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Background: Although preliminary reports suggest that ALK gene amplification may occur in inflammatory breast
cancer (IBC), data are limited. We performed a comprehensive investigation of the status of ALK gene in IBC.
Methods: We used core biopsy (CB) samples from 30 IBC patients for immunohistochemistry (IHC), 25 of these
samples for fluorescence in situ hybridization (FISH) of ALK gene rearrangement, 8 for chromosome 2 aneusomy,
and 20 microdissected frozen CBs for array comparative genomic hybridization (CGH) and mRNA analysis.
Results: All 30 samples were negative for ALK protein expression by IHC. FISH analysis showed no EML4-ALK gene
rearrangement in any samples, although 16 of the 25 samples (64%) contained 3 to 4 extra copies of the ALK gene,
and chromosome 2 aneusomy was found in 7 of 8 samples that had extra copies of the ALK gene. Only 3 of the 20
samples showed evidence of mild ALK gene amplification by array CGH. mRNA analysis revealed that mRNA
expression of ALK was not significantly higher in these samples compared with samples that showed no evidence
of ALK gene amplification in CGH analysis, nor was mRNA expression of ALK significantly different in tumor
compared with 5 normal breast samples (P > 0.05, t test).
Conclusion: Our comprehensive evaluation suggests that ALK gene rearrangement did not occur in the IBC
patients studied. The significance of our finding of mildly increased copy numbers of the ALK gene resulting from
chromosome 2 aneusomy rather than mild amplification of the ALK gene requires further investigation.Introduction
The anaplastic lymphoma kinase (ALK) gene belongs to
the insulin receptor superfamily and encodes a receptor
tyrosine kinase that is normally expressed in select neur-
onal cell types (Pulford et al. 1997; Morris et al. 1997;
Iwahara et al. 1997). Aberrant ALK activity resulting from
point mutations, amplifications, chromosomal transloca-
tions, or other types of rearrangements has been impli-
cated in the pathogenesis of selected human cancers. ALK
was first identified as a fusion partner of nucleophosmin
in anaplastic large-cell lymphoma resulting from t(2,5)
(p23;q35) chromosomal translocation (Morris et al. 1994;
Shiota et al. 1994). Chromosomal translocations linking
ALK to other fusion partners in anaplastic large-cell
lymphoma, inflammatory myofibroblastic tumors, and* Correspondence: skrishna@mdanderson.org
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reproduction in any medium, provided the origneuroblastomas have been established subsequently
(Pulford et al. 2004; Lawrence et al. 2000; George et al.
2008; Chen et al. 2008; Janoueix-Lerosey et al. 2008;
Mossé et al. 2008).
Recently, a novel gene fusion involving ALK and echino-
derm microtubule-associated protein-like 4 (EML4) was
discovered in non-small cell lung carcinoma (NSCLC)
(Soda et al. 2007; Mano 2008). This gene fusion was
reported to result from a small inversion within the short
arm of chromosome 2 involving an almost identical por-
tion of ALK exons (20–29) representing the intracellular
domain of the molecule and various portions of the EML4
exons (Soda et al. 2007; Wong et al. 2009; Takeuchi et al.
2008; Choi et al. 2008; Koivunen et al. 2008; Takeuchi
et al. 2009). The presence of intact ALK kinase domain in
a fusion protein resulting from ALK rearrangement results
in transformation as well as oncogenic activity in the cells.
(Soda et al. 2007; Choi et al. 2008; Soda et al. 2008).This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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reported to lead to cell cycle arrest and apoptosis in ana-
plastic large-cell lymphoma, NSCLC, and neuroblastoma
cells with any of the noted ALK rearrangements (Wan
et al. 2006; Christensen et al. 2007; Galkin et al. 2007;
McDermott et al. 2008). Multiple small-molecule ALK
inhibitors have been developed to antagonize cells with
the EML4-ALK fusion.
Although EML4-ALK gene rearrangement has been
studied in solid tumors such as NSCLC, few studies have
investigated their role in breast cancers. A recent report
described a possible role for ALK amplification in inflam-
matory breast cancer (IBC) (Robertson et al. 2011). Recent
research has focused on understanding the genomic
makeup of IBC to account for its distinct clinical presenta-
tion and biology compared with other types of breast can-
cer. An intense effort is also underway to unearth possible
targets for currently available therapeutic agents so that
patient outcomes can be improved with this very aggres-
sive variant of breast cancer. However, the role of ALK
gene and the implications of ALK amplification in IBC for
available targeted treatments using small-molecule ALK
inhibitors remain unclear.
To address all these knowledge gaps, we conducted a
comprehensive investigation of ALK gene in tumor sam-
ples from IBC patients using immunohistochemistry
(IHC) to evaluate ALK protein expression, fluorescence in
situ hybridization (FISH) for EML4-ALK rearrangement,
and array comparative genomic hybridization (CGH) and
transcriptional profiling to evaluate copy number and
mRNA levels of the ALK gene.
Materials and methods
Tumor samples
We used ultrasound-guided core needle biopsy (CNB)
tumor samples from 30 IBC patients under an Institutional
Review Board (The University of Texas MD Anderson
Cancer Center) approved protocol. The primary invasive
ductal carcinoma was categorized as Nottingham histologic
grade 2 in 12 of the 30 patients and as grade 3 in the
remaining 18 patients. Tumor samples from 12 patients
were positive for estrogen (ER) or progesterone receptors
(PR) but negative for human epidermal growth factor re-
ceptor 2 (HER2), samples from 13 patients were negative
for ER and PR but positive for HER2, and samples from 5
patients were negative for all 3 markers.
The CNB’s were fixed in formalin, routinely processed,
embedded in paraffin wax, and cut into 5-μm unstained
tissue for IHC staining and FISH. They were embedded
in optimal cutting medium (OCT), cut into 5-μm sec-
tions and stained with hematoxylin and eosin to confirm
the presence of invasive carcinoma with sufficient cellu-
larity (at least 75%) to be used for CGH and mRNA
analysis.IHC staining for ALK
Immunostaining was performed in a Bond max automatic
immunostainer (Leica). Heat-induced epitope retrieval
was performed on deparaffinized tissue sections using
Tris-EDTA buffer (pH 6.0). Primary monoclonal ALK
antibody (Dako™ Cytomation, Carpentaria, CA) at 1:25
dilution was applied on the tissue sections. Endogenous
peroxide was blocked using 3.0% hydrogen peroxide and
polymer horseradish peroxidase anti-mouse/anti-rabbit
IgG was applied on the slides. Diaminobenzidine was
added as the chromogen for signal recognition. Positive
staining was recognized as granular brown cytoplasmic
positivity in the tumor cells.
FISH for ALK gene rearrangement
To detect ALK gene rearrangement, we used the EML4-
ALK breakapart probe (Abbot™Laboratories, Des Plaines,
IL) in 25 of the samples. Unstained tissue sections were
baked for 24 hours at 56°C in a ThermoBrite temperature
controlled slide processing system (Abbott Molecular Inc.,
Des Plaines, IL) and immersed in Hemo-De solution. The
slides were immersed in Vysis™ pretreatment solution
(1 M sodium thiocyanate) at 80°C for 10 minutes, and
in protease solution (previously warmed to 37°C) for
10 minutes, washed with purified water, air-dried, and
dehydrated in ascending grades of alcohol.
Ten microliters of the ALK probe mixture was applied
on the air-dried slides. Denaturation and hybridization of
the tissue sections was performed using the Thermobrite
system (Abbott Molecular Inc. Des Plaines, IL), which was
programmed to 75°C for 5 minutes for the denaturation
process and 37°C for 16 hours for the hybridization of the
probes. The slides were then washed with 0.4X saline-
sodium citrate (SSC) solution at 70°C for 2 minutes and
2X SSC at room temperature for 3–5 minutes. Lastly,
10 μL of DAPI was applied on the slides; the slides were
examined using a fluorescent microscope.
FISH signals were counted in 50 tumor cells. The
breast tumor was considered positive for EML4-ALK
rearrangement when at least 1 set of orange and green
signals were 2 or more signals apart, a single orange sig-
nal was observed without a corresponding green signal,
or fused or broken apart signals were observed in 15% of
the tumor cells. The breast tumor was considered nega-
tive for EML4-ALK rearrangement when the orange and
green signals were adjacent or fused (appeared yellow),
orange and green signals were less than 2 signals apart,
or a single green signal was observed without a corre-
sponding orange signal.
FISH for CEP2
To detect aneusomy in chromosome 2, we performed
FISH using the CEP2 probe (Abbott Molecular™) in 8
samples with increased EML4-ALK signals. Five micron
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80 minutes and 30 minutes (pretreatment and protease,
respectively) using a VP 2000 (Abbott Molecular™, Des
Plaines, IL) instrumentation.
Slides were then pre-aged in 2X SSC/0.05% IGEPAL,
pH 7.0, for 5 minutes and dehydrated in 70%, 80%, and
100% cold ethanol for 1 minute each and then dried at
37°C for 5 minutes. 10 ul CEP 2 was placed on the target
area and co-denatured at 72.0°C for 6.5 minutes and
hybridized for 8 hours at 37°C, using a Thermobrite
instrument. The slides were subsequently washed in
2XSSC/0.05% IGEPAL for 2 minutes at 74°C followed by
2XSSC/0.05% IGEPAL for 1 minute at room temperature.
18 ul of DAPI/AF was applied, coverslip placed, and ana-
lyzed using a Nikon Eclipse fluorescence microscope.
Genomic DNA and RNA sample preparation
Twenty frozen tissue blocks were cut into 16-μm sec-
tions and manually dissected to obtain invasive tumor
cells which was used for genomic DNA and RNA extrac-
tion. In addition, 40–60 frozen sections of benign breast
tissue were used as controls for CGH and transcriptional
profiling.
Genomic DNA was extracted from cells using the
Quick Gene SP-kit (Fujifilm™, Tokyo, Japan), and quality
was characterized using agarose gel electrophoresis.
Human female genomic DNA (Novagen™, Billerica,
MA) was used for normal reference DNA. Total RNA
was extracted from the cells with RNeasy micro kit
(Qiagen™, Germantown, MD), and quality was charac-
terized using BioAnalyzer (Agilent Technologies™, Santa
Clara, CA).
Preparation of the whole-genome DNA microarray
We created a whole-genome DNA microarray with a tiling
resolution that included complete coverage of the human
genome, using 12,310 individually amplified bacterial arti-
ficial chromosome (BAC) clones. All BAC clones were
cultured in a single colony and validated with polymerase
chain reaction (PCR) amplification using clone-specific
primers. BstYI was restricted in the extracted BAC DNA,
and DNA was amplified using ligation-mediated PCR and
printed on glass slides using an inkjet-type spotter.
Array CGH analysis of genome copy number
Alu I and Rsa I-restricted genomic DNA was labeled by
random priming with Alexa555-dCTP (test DNA) and
Alexa647-dCTP (reference DNA) using the BioPrime
Plus ArrayCGH Indirect Genomic Labeling System
(Invitrogen, Macro Island, FL). Labeled test and refer-
ence DNA was precipitated with ethanol in the presence
of Cot-1 DNA, redissolved in a hybridization mix, and
denatured at 70°C for 10 minutes. After being incubated
at 42°C for 5 minutes, the mixture was applied to thewhole-genome DNA microarray (LinkGenomics, Tokyo,
Japan) and covered with a MAUI mixer hybridization
chamber (Biomicro Systems). After being incubated at
42°C for 48 hours, the slides were washed with 2X SSC/
0.1% sodium dodecyl sulphate (SDS) buffer and 0.1X
SSC/0.1% SDS buffer several times. The slides were then
rinsed with 0.01× SSC buffer and air-dried, scanned with
a Microarray Scanner (Agilent Technologies, Santa
Clara, CA), and analyzed using Gene-Pix Pro 4.0 im-
aging software (Axon Instruments, Inverurie, Scotland).
We performed normalization using global-normalization
methods and calculated the fold changes of gene amplifi-
cation compared with the normal tissue, focusing on 2
BAC clones (RP11-62B19 and RP11-701P18) covering the
regions containing the ALK gene (2p23). A G/R ratio ≥1.2
indicated a gain, and a G/R ratio ≤0.8 indicated a loss.
Microarray analysis of mRNA expression
Microarray analysis was performed using 20 tumor sam-
ples (the same samples used for CGH analysis) and 5
normal breast tissue samples. RNA samples were labeled
using the Low Input Quick Amp Labeling Kit (Agilent
Technologies, Santa Clara, CA). Labeled cRNA was
hybridized to an oligonucleotide microarray (Whole
Human Genome 4 × 44 K; Agilent Technologies) at 60°C
for 17 hours. The slides were washed with the Gene
Expression Wash Buffer Kit (Agilent Technologies,
Santa Clara, CA), dried, then scanned with an Agilent
Microarray Scanner and analyzed using the Feature
Extraction software version 9.5.1 (Agilent Technologies,
Santa Clara, CA). Normalization was performed using
global-normalization methods. The mRNA expression
was compared between tumor samples and normal breast
tissue samples using student t test.
Results
IHC staining for ALK
All 30 primary tumor samples were negative for ALK pro-
tein overexpression. Figure 1 illustrates a representative
case showing absence of ALK protein overexpression.
FISH for ALK gene rearrangement and CEP2
None of the 25 samples showed any evidence of separ-
ation of EML4 (green signals) and ALK (orange signals)
indicating the absence of EML4-ALK gene rearrange-
ment. However, in 16 (64%) of the 25 samples, we found
3 to 4 extra copies of adjacently placed EML4 and ALK
signals in 2-50% of the tumor cells. We evaluated 8 of
these samples for aneusomy of chromosome 2 using the
CEP2 probe.
The CEP2 analysis revealed evidence of aneusomy of
chromosome 2 in 7 (88%) of the 8 samples examined,
with 3–4 signals observed in 4-57% of the tumor cells.
Figure 2 illustrates a representative sample showing a
Figure 1 Hematoxylin and eosin staining (magnification x200; A) and ALK immunohistochemical staining (magnification x200; B) in a
representative sample of tumor tissue from a patient with inflammatory breast carcinoma. Note that the tumor cells are entirely negative
for ALK protein overexpression (B).
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evidence of chromosome 2 aneusomy (Figure 2B).
CGH analysis of genome copy number
Results of the CGH analysis using 2 BACs in the regions
containing the ALK gene are shown in Table 1. In 17
(85%) of the 20 samples examined, we did not observe
any gains of either of the 2 BAC clones (G/R ratio < 1.2),
indicating that no extra copies of the ALK gene were
present. A gain of only 1 BAC clone was observed in 2
samples and a gain of both BAC clones was observed in
1 sample. However, because the G/R ratios were low
(<1.3), this finding suggests low levels of ALK gene amp-
lification. In any case, ALK gene amplification was not
present in most of the samples that we examined.
Microarray analysis of mRNA expression
Results of transcriptional profiling are depicted in Figure 3.
mRNA expression of the ALK gene was not significantly
higher in the 20 tumor samples in comparison to the 5
normal breast tissue samples (p > 0.05, t test). The mRNA
expression of ALK in the RNA obtained from the 3
samples that showed possible ALK gene amplification inFigure 2 Fluorescence in situ hybridization results in a representative
carcinoma. Analysis using the Vysis ALK Break Apart probe (A) showed no
are present. Extra copies of CEP2 were also present (B), indicating aneusomthe CGH analysis was not significantly higher than in
the RNA from the 17 samples that did not show evi-
dence of ALK gene amplification in the CGH analysis
(p > 0.05, t-test).
Discussion
Our comprehensive evaluation of the status of ALK gene
did not reveal any evidence of ALK gene rearrangement,
mRNA overexpression or increased protein levels in IBC.
FISH analysis using dual color breakapart probes did not
show any evidence of EML4-ALK gene rearrangements. A
common occurrence in the FISH analysis of IBC tumors
was however the presence of a mild increase in copy num-
bers of the EML4-ALK signals in a fraction of the tumor
cells. The presence of increased copy numbers of the ALK
gene in IBC can be due to either ALK gene amplification
or aneusomy for chromosome 2, the parent chromosome
on which the ALK gene resides. By extending the FISH
analysis for EML4-ALK gene rearrangement with FISH
for chromosome centromere 2 (CEP 2) we could further
stratify patients in whom the increased copy numbers of
the ALK gene was a result of chromosome 2 aneusomy as
against those with true amplification of the ALK gene.sample of tumor tissue from a patient with inflammatory breast
evidence of fusion of the signals, but 2 extra copies of the ALK gene
y of the tumor cells for chromosome 2.
Table 1 Results of array comparative genomic
hybridization analysis of 20 tumor samples from patients
with inflammatory breast carcinoma
Sample no. G/R ratio





















For each bacterial artificial chromosome (BAC) clone, G/R ratios higher than 1.2
(indicating BAC clone gain and possible ALK gene amplification) are shown in
boldface type.
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was performed in only a small proportion of the IBC
tumors, the finding of aneusomy for chromosome 2 in
majority of the tested IBC patients (7/8) suggests that the
finding of mildly increased copy numbers of the ALK geneFigure 3 Results of transcriptional profiling showing mRNA expressio
inflammatory breast carcinoma and 5 normal breast tissue samples.by FISH resulted mostly from mildly increased copies of
chromosome 2 and not due to ALK gene amplification. In
rare patients with mildly increased copy numbers of the
EML4-ALK with diploid status of chromosome 2 it is
possible that there may be low levels of ALK gene amplifi-
cation. It is to be noted that although we found mild
increase in the copy numbers of the ALK gene in 64% of
the IBC patients by FISH analysis, alterations of copy
numbers of the ALK gene was detected in only 3 out of
the 20 patients by CGH analysis. The reason for such
discordance is most likely due to variable sensitivities of
the DNA probes utilized in the EML4-ALK breakapart
probes used in FISH and the 2 BAC clones used in CGH
analysis. The absence of elevated mRNA levels in any of
the patients by transcriptional profiling as well as the
absence of ALK protein overexpression by IHC suggests
that the functional significance of low-level amplification
of the ALK gene that can occur in occasional patients with
IBC without chromosome 2 aneusomy is perhaps limited.
It is to be acknowledged that the ALK antibody used in
the study may not be highly sensitive so as to detect low
levels of ALK protein overexpression. However, the
absence of elevated ALK mRNA levels in any of the IBC
patients provides support that the low level of gene ampli-
fication in occasional IBC patients may not be of clinical
significance. Nevertheless the possibility of triggering of
the downstream signaling pathways in the tumor cells as a
result of the mild increase in copy numbers of the ALK
gene with or without underlying chromosome 2 aneusomy
needs further investigation.
Very few studies have investigated the status of the ALK
gene in breast cancer. Grob et al. studied driver mutations
affecting the RAS/MAP kinase pathway in 65 samples of
triple-negative breast cancers (Grob et al. 2012). They did
not find any case of ALK gene rearrangements. Similarly,
Fukuyoshi et al. studied EML4-ALK fusion transcripts
using reverse transcriptase PCR and they did not find anyn levels of the ALK gene in 20 tumor samples from patients with
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genomic types of the breast carcinoma that were investi-
gated were not reported in this study.
To the best of our knowledge, only 1 study has
reported EML4-ALK fusion in breast carcinoma. Lin
et al. used profiling of cancer genomes on an exon array
to develop a novel computational method for searching
gene rearrangements in solid tumors (Lin et al. 2009).
They detected EML4-ALK fusion in 5 of 209 breast
carcinomas (2.4%). However, the genomic types of the
breast cancers that demonstrated EML4-ALK fusion
were not reported, nor is it known whether any of the 5
tumors that had the EML4-ALK fusion were associated
with clinicopathologic features characteristic of IBC.
An abstract by Robertson et al. is to the best of our
knowledge, the only report investigating the status of
the ALK gene in IBC (Robertson et al. 2011). During a
proteomic pathway analysis, the ALK pathway was
found to be activated in 3 different IBC cell lines, and
later genomic experiments showed that the ALK gene
was amplified in IBC cell lines and in 9 of the 12 tumor
samples analyzed. Activating mutations were not ob-
served, but ALK amplification was found to be a preva-
lent finding in proteomic-genomic evaluation. The
authors also reported that crizotinib, a small-molecule
inhibitor of ALK, arrested growth of IBC cells in vitro
and activated the cell death pathway. Moreover, xeno-
graft IBC tumors were resistant to paclitaxel but sensi-
tive to low doses of crizotinib, which resulted in tumor
shrinkage similar to that reported in ALK-driven
NSCLC models. ALK gene amplification was found to
be a common feature of IBC, and the authors suggested
that small-molecule ALK inhibitors could be effective in
mouse xenograft IBC models. In a subsequent commen-
tary related to the abstract published by Robertson
et al., Tuma suggested that validation with a clinical trial
was needed (Tuma 2012). However, our findings show-
ing that the extra copies of the ALK gene observed in
64% of the IBC patients were largely associated with
aneusomy of chromosome 2 led us to a different con-
clusion than that of Robertson et al. The results of our
comprehensive evaluation of the status of ALK gene
does not support the presence of EML4-ALK gene
rearrangements in IBC. Our finding of mildly increased
copy levels of the ALK gene in a majority of IBC
patients resulting as a consequence of chromosome 2
aneusomy and not due to amplification of the ALK gene
needs further validation in a larger cohort of IBC pa-
tients. The possible activation of downstream signaling
pathways resulting from the presence of extra copies of
the ALK gene in IBC warrants further exploration.Competing interests
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